#valeant

Big Pharma prices, profits soar

By Betsey Piette

Valeant

Some Reflections on US Healthcare From the Great White North

By Marvin Ross

Like many outside the US, I am perplexed by their health care system, the amount that is spent, and the poor results for citizens that it creates. Last year, I wrote in the Huffington Post about what I call my near death experience and contrasted by care and costs to that of the US. My key comment was that there should be no profit motive in health care.

I’ve just finished reading…

New Post has been published on https://is.gd/EpmvY5

NEW YORK | Valeant, a new business model and now, a new name

NEW YORK— Valeant Pharmaceuticals, which came under heavy scrutiny for acquiring the rights to drugs and then drastically raising their prices, is changing its name.

The Canadian company said Tuesday that it will now be called Bausch Health Companies.

CEO Joseph Papa said in a prepared statement that the name change is “a major step forward” in the company’s transformation.

Valeant Pharmaceuticals International Inc. fell into the crosshairs of Washington after an extended acquisition spree of other companies, followed by triple-digit price hikes on critical heart drugs and other medicines.

Its spate of acquisitions and soaring revenue propelled its stock through the roof, but it ran up a staggering $30 billion in debt — roughly three times its annual revenue.

Former CEO Michael Pearson, who formulated the strategy, was ousted in 2016.

__

By Associated Press – published on STL.News by St. Louis Media, LLC (Z.S)

Does Deutsche Bank Finally Have It Right on Valeant?

Valeant Pharmaceuticals International Inc. (NYSE: VRX) shares saw a handy gain on Monday after one key analyst upgraded the stock. The company posted its fourth-quarter results last week, and investors were not happy, so this report might come as a shock to some who were expecting the bears to take over. Deutsche Bank raised its rating to Buy from Hold, with a $ 20 price target. The firm said…

Shares of Valeant Pharmaceuticals International (VRX) have outperformed the market in the past year, but analysts warn the rally could be hard-pressed to continue.  Goldman Sachs analysts Dana Flanders and Christopher Staral initiated coverage on the stock with a Sell rating and an $ 18 price target on Wednesday, warning that while Valeant has made plenty of progr… Stocks to Watch